2025-11-24 - Analysis Report
Okay, here's a comprehensive analysis of TG Therapeutics Inc. (TGTX) based on the data provided.

**1) Return Rate Comparison:**

*   **Company Overview:** TG Therapeutics Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
*   **TGTX Cumulative Return:** 79.54%
*   **VOO (S&P 500) Cumulative Return:** 94.64%
*   **Divergence:** -15.1 (Relative Divergence: 21.1)
*   **Analysis:** TGTX has underperformed the S&P 500 (VOO) over the period examined. The current divergence of -15.1 indicates that TGTX's cumulative return is 15.1 percentage points lower than the S&P 500. A relative divergence of 21.1 suggests that the current divergence is relatively close to the minimum divergence observed.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha   | Beta  | Cap(B) |
|------------|--------|-------|---------|-------|--------|
| 2015-2017  | -5.0%  | 73.5% | -33.0%  | 0.1   | 1.3    |
| 2016-2018  | -12.0% | 73.5% | -27.0%  | 0.0   | 0.7    |
| 2017-2019  | 74.0%  | 74.1% | 52.0%   | 0.0   | 1.8    |
| 2018-2020  | 316.0% | 74.1% | 293.0%  | 0.1   | 8.3    |
| 2019-2021  | 124.0% | 74.1% | 78.0%   | 0.3   | 3.0    |
| 2020-2022  | -71.0% | 77.8% | -71.0%  | -0.0  | 1.9    |
| 2021-2023  | -284.0%| 77.8% | -285.0% | -1.0  | 2.7    |
| 2022-2024  | 56.0%  | 77.8% | 36.0%   | -1.0  | 4.8    |
| 2023-2025  | 80.0%  | 80.7% | 21.0%   | -0.1  | 5.1    |

*   **CAGR (Compound Annual Growth Rate):** Shows significant volatility, ranging from negative to very high positive values.
*   **MDD (Maximum Drawdown):** Consistently high, indicating significant potential for losses.
*   **Alpha:** Largely positive alpha during the periods of positive CAGR, indicating outperformance compared to the benchmark. Negative alpha during periods of negative CAGR, suggesting underperformance.
*   **Beta:** Relatively low beta values (close to 0) imply that the stock's price is not highly correlated with the market and responds weakly to the market as a whole. The period of 2021-2025 shows negative Beta, indicating the counter-reaction of the price with the market.

**2) Recent Stock Price Fluctuations:**

*   **Current Price:** $31.95
*   **Previous Close:** $30.45
*   **Change:** 4.93%
*   **5-day SMA:** 30.93
*   **20-day SMA:** 32.36
*   **60-day SMA:** 33.42

*   **Analysis:** The stock price is currently above its 5-day SMA, but below its 20-day and 60-day SMAs.  This suggests a recent upward trend, but it's still trading below longer-term averages. The 4.93% change from the previous close indicates a significant price movement.

**3) Technical Indicators and Expected Return:**

*   **MRI (Market Risk Indicator):** 0.8 (Medium Investment)
*   **RSI (Relative Strength Index):** 39.67 (approaching oversold)
*   **PPO (Percentage Price Oscillator):** -0.25 (bearish)
*   **Hybrid Signal:** cash_80%_Sell 80.0% of holdings (5528 shares - Risky - MRI:0.50) (Cash Ratio: 80% on 2025-10-16)
*   **Recent Divergence Change:** 1.2 (+) (Short-term increase)
*   **Expected Return:** -103.8%

*   **Analysis:**  The MRI suggests a medium investment risk. The RSI is approaching oversold levels, which *could* indicate a potential buying opportunity, *but* it's not a strong signal on its own. The negative PPO signals a bearish trend.  The Hybrid Signal suggests reducing exposure significantly by selling a large portion of holdings and moving to a high cash position. The recent short-term divergence increase is positive, but it contradicts the very negative Expected Return. A -103.8% expected return suggests significant potential losses if held long-term, and/or the model is not accurately predicting the value of the stock.

**4) Recent News & Significant Events:**

*   **Negative:** "The Earnings Caveat That Sent This Hot Biotech Diving" – Suggests potential issues with earnings reports and investor reaction. "$TGTX stock is down 9% today. Here's what we see in our data." - Indicates downward price movement.
*   **Mixed:** "TG Therapeutics, Inc. (NASDAQ:TGTX) Stock Has Shown Weakness Lately But Financials Look Strong" – Conflicting signals.  "TG Therapeutics: Positives From Q3'25 Earnings, But Competitors Progressing (TGTX)" - Suggests good earnings, but increased market competition.
*   **Positive:** "Deloitte Fast 500 names TG Therapeutics (NASDAQ: TGTX) among North America’s fastest-growing firms" – Indicates strong growth. "How to recover losses in TGTX stock - Take Profit & Reliable Price Action Trade Plans" - Suggests hope for price recovery.

*   **Analysis:** The news is mixed, with both positive and negative headlines. The negative news related to earnings and stock price decline is concerning. The positive news about growth is encouraging, but must be balanced against the other negative factors.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (Mean: 1.67)
*   **Target Price:** Average $44.29 (High: $60.00, Low: $13.00)
*   **Recent Rating Changes:** No changes provided

*   **Analysis:** Despite the mixed news and technical signals, analysts generally have a positive outlook on TGTX, with a "Buy" consensus and a substantial average target price significantly above the current price.  However, the wide range between the high and low target prices ($13 to $60) indicates considerable uncertainty among analysts.

**5) Recent Earnings Analysis:**

| 날짜       | EPS  | 매출      |
|------------|------|-----------|
| 2025-11-05 | 2.69 | 0.16 B$   |
| 2025-08-08 | 0.19 | 0.14 B$   |
| 2025-05-09 | 0.03 | 0.12 B$   |
| 2024-11-07 | 0.03 | 0.08 B$   |
| 2025-11-05 | 0.03 | 0.08 B$   |

*   **Analysis:** The most recent EPS (2.69) is *significantly* higher than previous quarters, suggesting a strong performance. Revenue has also been increasing steadily. However, there is a duplicate entry for 2025-11-05 with conflicting EPS and Revenue figures. This discrepancy needs clarification.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|----------------|
| 2025-09-30   | $0.16B  | 82.63%         |
| 2025-06-30   | $0.14B  | 86.58%         |
| 2025-03-31   | $0.12B  | 87.14%         |
| 2024-12-31   | $0.11B  | 85.77%         |
| 2024-09-30   | $0.08B  | 88.86%         |

**Capital and Profitability:**

| Quarter      | Equity | ROE      |
|--------------|--------|----------|
| 2025-09-30   | $0.61B | 64.37%   |
| 2025-06-30   | $0.28B | 10.20%   |
| 2025-03-31   | $0.24B | 2.13%    |
| 2024-12-31   | $0.22B | 10.49%   |
| 2024-09-30   | $0.19B | 2.02%    |

*   **Analysis:** Revenue is trending upwards. Profit margins are very high and relatively stable. Equity has increased significantly in the latest quarter. ROE (Return on Equity) is extremely high in the most recent quarter, indicating very efficient use of shareholder equity to generate profits.

**7) Comprehensive Analysis (Summary):**

TGTX presents a mixed picture.

*   **Positives:**
    *   Strong recent earnings and revenue growth.
    *   Very high profit margins.
    *   Analysts have a "Buy" consensus and high price targets.
    *   Identified as a fast-growing firm.
    *   Significant increase in Equity and ROE in the latest quarter.
*   **Negatives:**
    *   Underperformance relative to the S&P 500.
    *   High Maximum Drawdown historically.
    *   Bearish technical indicators (PPO).
    *   Hybrid Signal suggests selling and moving to cash.
    *   A recent news headline highlights earnings issues.
    *   The Expected Return indicates significant long-term loss potential.
*   **Concerns:**
    *   The very high recent EPS (2.69) is a positive surprise, but should be treated with caution until confirmed that it is sustainable.
    *   Discrepancy in the earnings data needs clarification (the duplicate 2025-11-05 entry).
    *   The negative expected return contradicts positive aspects of the data.
*   **Overall Recommendation:** Due to the conflicting signals and high potential risks, a **cautious approach** is warranted. The negative expected return, selling signal, and high MDD, when combined, outweigh the positives. It's important to investigate the discrepancy in the earnings data and understand the reasons behind the negative expected return before making any investment decisions. The strong growth and analyst ratings are encouraging, but need to be balanced against the significant risks.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.